LIVE
RARE
Ultragenyx Pharmaceutical Inc. · Healthcare
$32.12
+31.89% this month
VERSUS
⟷
COMPARE
ALNY
Alnylam Pharmaceuticals, Inc. · Healthcare
$282.78
-0.02% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
RARE
3
ALNY
1
Comparison scoreboard
RARE LEADS 3/5AI Score
RARE 25.3
ALNY ✓57.5
1Y Return
RARE ✓+9.87%
ALNY -10.44%
Fwd P/E
RARE ✓20.71
ALNY 20.99
Target Up.
RARE ✓+63.56%
ALNY +54.68%
Op. Margin
RARE N/A
ALNY N/A
Metrics last refreshed: 7/14/2026
Quick take
RARE vs ALNY: Ultragenyx vs Alnylam Stock Comparison: AI Score, Valuation, Performance and Upside
Ultragenyx is a commercial rare disease company pivoting toward gene therapy with a diversified approved product portfolio, while Alnylam is the world leader in RNA interference therapeutics with multiple approved drugs and a large ATTR amyloidosis market opportunity. Alnylam is the more advanced and validated rare disease platform; Ultragenyx has gene therapy optionality.
RARE vs ALNY is a gene therapy-pivoting rare disease biotech versus the world's leading RNA interference medicines company — Alnylam has more validated commercial revenue and a larger market opportunity; Ultragenyx offers gene therapy upside at an earlier stage of execution.
Live analysis · updated 7/14/2026
RARE holds the edge across 3 of 5 key metrics in this comparison. RARE leads on both 1-year return (+9.87%) and forward P/E quality (20.71x vs 20.99x for ALNY), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for RARE (+63.56%) than for ALNY (+54.68%).
Normalized 1Y performance
RARE
ALNY
Recent returns
RARE
ALNY
Analyst price targets & sentiment
RARE · 19 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.5/5.0)
Price target range
analyst low$25.00
analyst high$96.00
analyst mean$52.53
current price$32.12
+63.6% upside to analyst mean
ALNY · 24 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.8/5.0)
Price target range
analyst low$310.00
analyst high$550.00
analyst mean$437.42
current price$282.78
+54.7% upside to analyst mean
Who should consider this stock?
RARE may suit investors who:
- →want rare disease exposure with gene therapy pipeline as additional upside
- →value Crysvita and Dojolvi as commercial products that fund R&D without full burn
- →believe gene therapy will become a standard treatment modality for metabolic rare diseases
- →are comfortable with extended profitability timeline as gene therapy pipeline advances
ALNY may suit investors who:
- →prefer the world leader in validated RNA interference medicines with multiple approved drugs
- →value the ATTR amyloidosis market as a large, growing, underpenetrated revenue opportunity
- →want the more commercially advanced rare disease and cardiovascular RNAi platform
- →are comfortable with competitive ATTR landscape and payer scrutiny on high-cost drugs
Performance & AI score
| Metric | RARE | ALNY |
|---|---|---|
| AI score | 25.3 | 57.5 |
| AI rank | #2849 | #252 |
| Latest close | $32.12 | $282.78 |
| 1M return | +31.89% | -0.02% |
| 6M return | +31.78% | -23.76% |
| 1Y return | +9.87% | -10.44% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RARE | ALNY |
|---|---|---|
| 1Y ago | $10.99K (+9.9%) started 2025-07-14 | $8.96K (-10.4%) started 2025-07-14 |
| 5Y ago | $3.79K (-62.1%) started 2021-07-14 | $16.6K (+66.0%) started 2021-07-14 |
| 10Y ago | $6.48K (-35.2%) started 2016-07-14 | $44.88K (+348.8%) started 2016-07-14 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | RARE | ALNY |
|---|---|---|
| Market cap | $3.16B | $37.75B |
| Trailing P/E | N/A | 73.83 |
| Forward P/E | 20.71 | 20.99 |
| Price/Sales | 4.72 | 8.81 |
| EV/Revenue | 6.05 | 8.96 |
| Analyst target | $52.53 | $437.42 |
| Target upside | +63.56% | +54.68% |
Growth, profitability & risk
| Metric | RARE | ALNY |
|---|---|---|
| Revenue growth | -2.20% | 96.40% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | -32.70% | +4.78% |
| Operating margin | N/A | N/A |
| Profit margin | -90.90% | 12.55% |
| ROIC proxy | N/A | 90.36% |
| Return on equity | N/A | 90.36% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 0.31 | 0.27 |
| Debt/equity | N/A | 276.20 |
| Current ratio | 2.02 | 3.13 |
| Quick ratio | 1.65 | 2.88 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
RARE max drawdown49.37%
ALNY max drawdown43.39%
RARE max wkly drop41.13%
ALNY max wkly drop14.54%
5Y risk snapshot
RARE max drawdown81.93%
ALNY max drawdown43.39%
RARE max wkly drop41.13%
ALNY max wkly drop20.65%
10Y risk snapshot
RARE max drawdown89.57%
ALNY max drawdown59.95%
RARE max wkly drop41.13%
ALNY max wkly drop49.44%
Performance metrics by period
| Period | Metric | RARE | ALNY |
|---|---|---|---|
| 1Y | Growth | +9.87% | -10.44% |
| CAGR | +9.88% | -10.45% | |
| Sharpe ratio | 0.46 | -0.23 | |
| Max drawdown | 49.37% | 43.39% | |
| Max daily drop | 42.32% | 6.87% | |
| Max wkly drop | 41.13% | 14.54% | |
| 5Y | Growth | -62.10% | +66.01% |
| CAGR | -17.64% | +10.67% | |
| Sharpe ratio | -0.15 | 0.35 | |
| Max drawdown | 81.93% | 43.39% | |
| Max daily drop | 42.32% | 17.10% | |
| Max wkly drop | 41.13% | 20.65% | |
| 10Y | Growth | -35.17% | +348.79% |
| CAGR | -4.24% | +16.20% | |
| Sharpe ratio | 0.12 | 0.46 | |
| Max drawdown | 89.57% | 59.95% | |
| Max daily drop | 42.32% | 48.49% | |
| Max wkly drop | 41.13% | 49.44% |
Business comparison
| Category | RARE | ALNY |
|---|---|---|
| Company | Ultragenyx Pharmaceutical Inc. | Alnylam Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | N/A | N/A |
| Core business | Rare disease biopharmaceutical company with approved treatments including Crysvita (X-linked hypophosphatemia), Dojolvi (LC-FAOD), and Evkeeza (homozygous familial hypercholesterolemia). Ultragenyx's pipeline emphasizes gene therapy for rare metabolic disorders. | RNA interference (RNAi) therapeutics leader with multiple approved drugs: Onpattro, Givlaari, Oxlumo, Leqvio (co-commercialized with Novartis), and Amvuttra for ATTR amyloidosis. RNAi silences disease-causing genes by degrading mRNA before protein production. |
| Investor focus | Crysvita global revenue ramp, gene therapy clinical progress, pipeline acceleration, and path to profitability as commercial products scale. | Amvuttra and Leqvio revenue ramp, ATTR amyloidosis market penetration, royalties from Novartis Leqvio co-promotion, and pipeline advancement in cardiovascular disease. |
RARE strengths
- →Diversified commercial rare disease portfolio provides revenue while gene therapy pipeline advances
- →Gene therapy expertise positions Ultragenyx in a next-generation treatment modality for rare genetic disorders
- →Strong orphan drug designation history provides regulatory and commercial exclusivity advantages
ALNY strengths
- →Alnylam has validated the RNAi platform with multiple approved drugs across rare diseases and cardiovascular conditions
- →ATTR amyloidosis market for Amvuttra is large and growing — millions of undiagnosed patients represent significant upside
- →Leqvio partnership with Novartis provides commercial muscle without full Alnylam marketing investment
Risks to watch — RARE
- →Rare disease drugs face reimbursement challenges from payers who scrutinize high-cost treatments
- →Gene therapy programs are earlier-stage with uncertain clinical and regulatory timelines
- →Profitability timeline remains extended as R&D investment for gene therapy is significant
Risks to watch — ALNY
- →Competitive landscape for ATTR amyloidosis includes Pfizer (tafamidis) and other gene silencing approaches
- →RNAi drug pricing is subject to payer scrutiny in rare disease and now cardiovascular populations
- →Pipeline beyond ATTR and cardiovascular requires further clinical validation to sustain premium valuation
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →